GLP-1 reduces the risk of glaucoma in obese people

OPHTHALMOLOGY JOURNAL GLP-1 reduces risk of eye disease in obese people Use of GLP-1 receptor agonists (GLP-1-RA) can reduce the risk of primary open-angle glaucoma (POAG) and ocular hypertension in obese patients without diabetes. This is shown by a foreign registry study, which gives extra wind in the sails of Danish researchers' hypotheses about the effect of the GLP-1-RA semaglutide against glaucoma.